A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A Virus
A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A Virus
批准号:
10216937
负责人:
Juergen A Richt
金额:
$19.88万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-15 至 2023-06-30
关键词:
Animal ModelAnimalsB-LymphocytesCessation of lifeClinicalClinical ResearchComplementContainmentDevelopmentDevelopment PlansDiseaseDoseEconomicsEnzyme-Linked Immunosorbent AssayEpidemicExposure toFamily suidaeHaplotypesHealthcare SystemsHomoHospitalizationHumanImmuneImmune responseImmunityImmunologic MonitoringImmunologicsInactivated VaccinesInbreedingInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A virusInfluenza vaccinationKnowledgeLongitudinal StudiesLung diseasesMembrane ProteinsModelingMonitorMorbidity - disease rateMusNational Institute of Allergy and Infectious DiseaseOutcomePathologyPopulationPublic HealthPublishingRespiratory Tract InfectionsSeasonsStrategic PlanningStressStudy modelsSymptomsT-LymphocyteTestingTimeUpper Respiratory InfectionsVaccinatedVaccinationVaccinesViral ProteinsVirulentVirusVirus DiseasesVirus ReplicationWeight GainWorkage groupcosteconomic costexperimental studyfeasibility testinginfluenza infectioninfluenza virus straininfluenza virus vaccineinfluenzavirusmouse modelneutralizing antibodynovelpandemic diseaseporcine modeltooluniversal influenza vaccineuniversal vaccinevaccination strategyvaccine developmentvaccine evaluationvaccine responsevaccine trial
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Influenza viruses cause infections of the respiratory tract in both humans and pigs. Antigenic drift allows viruses to escape pre-existing immunity present in the human population and cause annual epidemics that results in significant morbidity, economic loss, and an estimated 250,000 deaths per year worldwide. Antigenic shift allows the creation of new influenza viruses with novel surface proteins that are antigenically unrelated to surface proteins of viruses that circulated in previous seasons. Currently licensed vaccines aim at the induction of neutralizing antibodies and their efficacy depends on accurate prediction of the influenza strains that will circulate in the next season. Protection provided by current vaccines is limited in time since antigenic drift and shift allow influenza viruses to escape vaccine-induced neutralizing antibodies, and there is a critical need for broad and long-lasting vaccines that provide protection against influenza viruses of different subtypes in all age groups. The development of such universal influenza vaccines is of public health importance and the outlines of a strategic plan have been published recently by the National Institute of Allergy and Infectious Diseases. One of the action items is to develop animal models that recapitulate human immunity to influenza virus infection and vaccination. In this project proposal, we plan to further develop the miniature pig model for the study of host-immune responses to influenza A virus infection and vaccination. We choose to work with miniature pigs because they are natural influenza hosts, easier to handle and to obtain seronegative animals than with conventional pigs and because haplotyped inbred animals are available. In the first part of the project we will focus on the establishment of an influenza A infection and re-infection model with miniature pigs to complement clinical studies previously performed in humans and the conventional pig influenza model. Immune responses induced by the first influenza infection will be monitored and correlated with protection against re-infection with a heterosubtypic influenza virus. In the second part of the project we will focus on the establishment of an influenza A vaccine model with miniature pigs to evaluate universal vaccine approaches and compare them to a conventional influenza vaccine. We will also investigate if the miniature pig influenza model is suitable for the study of vaccine-associated enhancement of disease, as is described for conventional pigs. This project will allow to define correlates of protective immunity against influenza A viruses of different subtypes and is crucial to close knowledge gaps in the current models for universal influenza vaccine studies.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in QIV vaccinated mice.
用于佐剂制剂的脂质纳米颗粒组合物在QIV疫苗接种的小鼠中调节流感病毒感染后的疾病。
DOI:
10.1101/2024.01.14.575599
发表时间:
2024
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Jangra,Sonia, Lamoot,Alexander, Singh,Gagandeep, Laghlali,Gabriel, Chen,Yong, Yz,Tingting, García-Sastre,Adolfo, DeGeest,BrunoG, Schotsaert,Michael]
通讯作者:
Schotsaert,Michael
Center on Emerging and Zoonotic Infectious Diseases
-
批准号:10642671
-
项目类别:
-
资助金额:$226.01万
-
财政年份:2020
-
负责人:Juergen A Richt
-
依托单位:
Administrative Core
-
批准号:10642672
-
项目类别:
-
资助金额:$98.04万
-
财政年份:2020
-
负责人:Juergen A Richt
-
依托单位:
Center on Emerging and Zoonotic Infectious Diseases
-
批准号:10397670
-
项目类别:
-
资助金额:$226.34万
-
财政年份:2020
-
负责人:Juergen A Richt
-
依托单位:
Administrative Core
-
批准号:10397671
-
项目类别:
-
资助金额:$77.66万
-
财政年份:2020
-
负责人:Juergen A Richt
-
依托单位:
Pathogenesis, Transmission and Genetic forms of BSE
-
批准号:8129594
-
项目类别:
-
资助金额:$49.28万
-
财政年份:--
-
负责人:Juergen A Richt
-
依托单位:
Pathogenesis, Transmission and Genetic forms of BSE
-
批准号:8307859
-
项目类别:
-
资助金额:$53.57万
-
财政年份:--
-
负责人:Juergen A Richt
-
依托单位:
Pathogenesis, Transmission and Genetic forms of BSE
-
批准号:7934046
-
项目类别:
-
资助金额:$48.32万
-
财政年份:--
-
负责人:Juergen A Richt
-
依托单位:
Pathogenesis, Transmission and Genetic forms of BSE
-
批准号:8381057
-
项目类别:
-
资助金额:$52.73万
-
财政年份:--
-
负责人:Juergen A Richt
-
依托单位:
海外基金